Dateline City:
WHITEHOUSE STATION, N.J.
Phase 3 Clinical Trial Enrollment Scheduled to Start by the End of 2014
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the presentation of results from a Phase 2b clinical
trial evaluating the safety and efficacy of once-daily oral doravirine,
an investigational next-generation non-nucleoside reverse transcriptase
inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to
efavirenz plus TDF/FTC in previously untreated patients with HIV-1
infection. Results were presented as a poster (#0434) and oral
presentation by Dr.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orCarmen de Gourville, 267-664-0146orInvestors:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more